Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)-- #ILT4--Immune-Onc to Present Preclinical and Clinical Posters on IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at AACR 2022 Meeting
